2 results
Approved WMOCompleted
The objective of the trial is to confirm efficacy and a favorable benefit-risk ratio for BIBF 1120 in the treatment of IPF at the dose of 150 mg bid compared to placebo.
Approved WMORecruiting
In this study we want to evaluate the safety and efficacy of the new drug ZPL389. ZPL389 is tested in various strengths in patients with moderate or severe atopic dermatitis. The effects of ZPL389 are compared with those of a placebo.